Introduction: Osimertinib is an oral, central nervous system-active, EGFR tyrosine kinase inhibitor (TKI) for the treatment of EGFR T790M-positive advanced NSCLC. Here we have evaluated EGFR mutation frequencies in two phase II studies of osimertinib (AURA extension and AURA2).
Methods: After progression while receiving their latest line of therapy, patients with EGFR mutation-positive advanced NSCLC provided tumor samples for mandatory central T790M testing for the study selection criteria. Tumor tissue mutation analysis for patient selection was performed with the Roche cobas EGFR Mutation Test (European Conformity-in vitro diagnostic, labeled investigational use only) (Roche Molecular Systems, Pleasanton, CA). Patients should not have been prescreened for T790M mutation status. The cobas test results were compared with those of the MiSeq next-generation sequencing system (Illumina, San Diego, CA), which was used as a reference method.
Results: Samples from 324 and 373 patients screened for AURA extension and AURA2, respectively, produced valid cobas test results. The T790M detection rates were similar between AURA extension and AURA2 (64% and 63%, respectively). The pooled T790M rate was 63%, with no difference by ethnicity (63% for Asian and non-Asian patients alike) or immediately prior treatment with an EGFR TKI (afatinib, 69%; erlotinib, 69%; and gefitinib, 63%). A higher proportion of patients had T790M detected against a background of exon 19 deletions versus L858R mutation (73% versus 58% [p ¼ 0.0002]). In both trials the cobas test demonstrated high sensitivity (positive percent agreement) and specificity (negative percent agreement) for T790M detection when compared with the next-generation sequencing reference method: positive percent agreement *Corresponding author.
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Introduction
The presence of sensitizing EGFR mutations is predictive of treatment benefit with EGFR tyrosine kinase inhibitors (TKIs) (e.g., erlotinib, gefitinib, or afatinib) in patients with advanced NSCLC.
1-3 Therefore, EGFR mutation testing is now considered standard of care in the work-up of these patients. [4] [5] [6] Despite the high response rates with first-line EGFR TKIs, disease progression occurs in most patients within 9 to 13 months after initiation of treatment. [1] [2] [3] 7 Among these patients, the most frequently observed resistance mechanism is the EGFR T790M mutation, which is estimated to be present in 50% to 60% of patients after disease progression during gefitinib, erlotinib or afatinib therapy. [8] [9] [10] [11] [12] [13] [14] Osimertinib is an oral, potent, central nervous system-active, irreversible EGFR TKI that is selective for both sensitizing EGFR and T790M resistance mutations. [15] [16] [17] After positive outcomes from phase I, II, and III trials, [18] [19] [20] [21] osimertinib was recommended for the treatment of patients with EGFR T790M-positive advanced NSCLC who progressed while receiving firstline EGFR TKI therapy. 5, 6 In two phase II single-arm studies, AURA extension and AURA2, osimertinib, 80 mg once daily, resulted in objective response rates of 62% and 70%, respectively, as assessed by blinded independent central radiological review with manageable side effects in patients with pretreated EGFR T790M-positive advanced NSCLC. 19, 20 In both studies, patients with EGFR mutation-positive advanced NSCLC who had received at least one prior regimen containing an EGFR TKI were selected for treatment with osimertinib if before study entry, the T790M mutation was detected in a tissue biopsy sample taken after disease progression during or after the previous regimen. Testing was centrally performed with the cobas EGFR Mutation Test (Roche Molecular Systems, Pleasanton, CA).
Using data from the screened populations from AURA extension, AURA2, and pooled AURA extension plus AURA2 data, we investigated the detection rates for EGFR T790M, common sensitizing mutations (exon 19 deletion and L858R), and rare EGFR mutations. We also evaluated whether ethnicity and type of EGFR TKI used in the immediately prior treatment affected detection rates.
Methods

Study Design
AURA extension and AURA2 were global phase II, open-label, multicenter studies of osimertinib in patients with T790M-positive advanced NSCLC who had progressed after prior therapy with an EGFR TKI (with or without additional anticancer regimens). Full details of the trial designs and interventions have been previously reported.
19,20
Participants
Patients were enrolled at study centers in 12 countries (Australia, Canada, France, Germany, Hong Kong, Italy, Japan, the Republic of Korea, Spain, the Republic of China, the United Kingdom, and the United States). Patients in both AURA extension and AURA2 were at least 18 years old (!20 years old in Japan) with a histologically or cytologically confirmed diagnosis of NSCLC plus documented evidence of EGFR mutation status and radiological progression during the most recent treatment regimen. Confirmation of EGFR T790M mutation status was performed by a central laboratory using the cobas EGFR Mutation Test (referred to as cobas test in the "Results" and "Discussion" sections) on a biopsy sample obtained after disease progression during or after the most recent treatment regimen. The central cobas EGFR Mutation Test results also provided information on other detectable EGFR mutations, such as common sensitizing mutations (exon 19 deletion and L858R) and rare EGFR mutations, the outputs of which are reported in this article. For key inclusion and exclusion criteria, refer to previous publications by Goss et al. 20 and Yang et al. 19 Standard Protocol Approvals, Registration, and Patient Consent All participating sites obtained approval from their independent institutional review boards or independent ethics committees. The studies were performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with International Council on Harmonization/Good Clinical Practice guidelines and applicable regulatory requirements. All patients provided written informed consent before their participation in the studies. The study protocols were designed by the sponsor (AstraZeneca) and the study investigators.
Mutation Analysis
Tumor Biopsy. Tumor samples were collected from primary or metastatic tumor sites after disease progression during or after the latest line of therapy. In AURA2, the tumor biopsy sample for mutation analysis was not permitted to be taken from a lesion that would be a target lesion for Response Evaluation Criteria in Solid Tumors assessment. Tissue available from a biopsy sample taken after confirmation of disease progression during the most recent treatment regimen could be submitted for T790M mutation testing with no requirement for a further biopsy sample, providing no further line of therapy had been administered. A further biopsy sample could be submitted for central testing if the first biopsy sample failed histopathologic review but not if it failed diagnostic testing or if a valid negative result was obtained. Investigators were instructed not to prescreen patients for enrollment.
Histopathological Analysis. Tumor samples were formalin-fixed and paraffin-embedded (FFPE). Blocks were requested wherever possible, but if not, 10 to 20 slides of freshly prepared consecutive, unstained 5-mm sections from the screening tumor block could be provided instead.
The FFPE tissue blocks were sectioned into 5-mm slices and mounted on slides. The middle sections were stained with hematoxylin and eosin and analyzed by a laboratory pathologist to assess tissue characteristics and tumor content by area and to determine whether macrodissection was required according to the cobas test instructions for use.
Cobas Test. Histopathologic assessment and EGFR mutation testing were performed at one of three central contract laboratories using the cobas EGFR Mutation Test (European Conformity-in vitro diagnostic, labeled investigational use only for study purposes). This test has a limit of detection of 2.4% to 3.0% for T790M against a background of 95% wild-type alleles in FFPE tumor samples when using 50 ng of DNA per amplification reaction (50 mL). 22 It is a real-time polymerase chain reaction test for the qualitative detection and identification of 42 somatic mutations in exons 18 to 21 of the tyrosine kinase domain of the EGFR gene (including the T790M mutation and the common EGFR sensitizing mutations, exon 19 deletions and L858R mutation) in DNA derived from FFPE human NSCLC tumor tissue. 22 Testing was performed by trained staff according to the cobas instructions for use at Carolinas Pathology Group (in the United States), Histogenex (in Europe), and Quintiles Singapore (in Asia).
DNA was quantified by using a spectrophotometer and normalized to 2 ng/mL before testing. Macrodissection was performed on samples with less than 10% tumor cells to enrich the samples before DNA extraction. Repeat testing was performed by using the same DNA extract a maximum of two times in samples in which EGFR mutation status could not be determined on account of an invalid run control or an invalid internal control. Samples were classified as invalid if repeat testing yielded no test result.
MiSeq NGS. Next-generation sequencing (NGS) can be a highly sensitive detection method for DNA variants present in samples. A proprietary NGS protocol, using Illumina's MiSeq platform (Illumina, San Diego, CA) was developed by Roche Molecular Systems and used as a comparator for the cobas EGFR Mutation Test. This involved a two-tube amplicon assay with a minimum read depth of 10,000 reads (median range 50,000 to 100,000, depending on the mutation) to sequence EGFR exons 18 to 21 only (performed by Roche Molecular Systems and SeqWright [Houston, TX]).
Statistical Analyses
The following parameters were recorded: percentage of samples passing histopathological review, percentage test success and percentage with an invalid result, EGFR test result, percentage of T790M positive/negative mutation combinations, effect of the type of immediately prior EGFR TKI treatment on T790M mutation rates, and mutation rate by ethnicity. Statistical tests were performed with Statistical Analysis Software (SAS Institute, Inc., Cary, NC).
The agreement between the cobas tissue test and NGS tissue test (reference) for each EGFR mutation subtype was assessed by calculation of the positive percent agreement (PPA), negative percent agreement (NPA), and overall percent agreement (OPA) with 95% confidence intervals (CIs) (determined by the ClopperPearson method). The PPA value relates to the sensitivity of the test, the NPA value relates to the specificity of the test, and the OPA value relates to the overall concordance of the tests. The calculations for each of these percent agreement comparisons are as follows:
where a is the number of samples that were mutation positive according to both tests and b is the number of samples that were mutation negative according to the reference method and positive according to comparative test. The value c is the number of samples that were positive according to the reference test and negative according to the comparative test, and d is the number of samples that were negative according to both tests. CIs were calculated by using the Clopper-Pearson exact method for binomial proportions.
Results
In AURA extension, 401 patients were screened, of whom 346 provided samples for histopathological review (Fig. 1) . In AURA2, 472 patients were screened, of whom 417 provided samples for histopathological review. In total, 327 patient samples (95%) in AURA extension and 383 patient samples (92%) in AURA2 passed histopathological review (see Fig. 1 ) and of these, 324 of 327 in AURA extension (99%) and 373 of 383 in AURA2 (97%) produced a valid cobas test result (N ¼ 697 in the pooled analysis set). The proportions of samples from Asian and non-Asian patients in AURA extension were 58% (n ¼ 187) and 42% (n ¼ 137), and in AURA2 they were 65% (n ¼ 244) and 35% (n ¼ 129), respectively, which is in line with the slightly different distribution of countries participating in the two studies.
The rate of T790M detection was similar in AURA extension and AURA2: 207 of 324 patients (64%) and 233 of 373 patients (62%), respectively ( Table 1 ). The rate of T790M detection in the pooled phase II analysis was 63% (440 of 697). In both studies, there was a higher proportion of patients with an exon 19 deletion than with an L858R mutation: 63% versus 30% in AURA extension and 55% versus 34% in AURA2 (see Table 1 ). Among patients with detectable T790M from the pooled analysis, 297 of 440 (68%) had a co-occurring exon 19 deletion and 130 of 440 (30%) had a co-occurring L858R mutation.
The frequency of exon 19 deletion and T790M mutation subtypes was similar between studies and between Asian and non-Asian patients (see Table 1 ). In the pooled analysis, the respective frequencies in Asian and non-Asian populations for exon 19 deletion were 57% and 61% (Fisher's exact two-sided test [p ¼ 0.3839]) and for T790M 63% and 63% (see Table 1 ). There was some evidence to suggest that L858R is statistically more frequent in Asian than non- (Fig. 2) . In the pooled analysis, the frequencies of co-occurring exon 19 deletions with T790M for the different prior EGFR TKIs were as follows: for gefitinib, 86 of 118 (73%); for erlotinib, 101 of 151 (67%); and for afatinib, 30 of 56 (54%). Also in the pooled analysis, the frequencies of co-occurring L858R mutations were as follows: for gefitinib, 32 of 118 (27%); for erlotinib, 45 of 151 (30%); and for afatinib, 22 of 56 (39%) (see Fig. 2 ).
We observed a higher proportion of patients with tumors harboring an exon 19 deletion testing positive for the T790M mutation at screening than those with an L858R mutation in both AURA extension (72% versus 54%) and AURA2 (73% versus 61%) ( objective response. One patient with T790M, S768I, and exon 19 deletion mutations detected in the tumor sample experienced disease progression. In the six patients with T790M as the only detectable EGFR mutation, four had a partial response to osimertinib and two had a best response of stable disease. In both studies, the cobas test demonstrated high sensitivity and specificity for T790M detection when compared with the NGS reference method. Of 327 patient samples in AURA extension that passed pathology review, adequate tissue for NGS testing was available from 293 (90%). Their PPA (excluding invalid results) was 91% (95% CI: 87-95), the NPA was 97% (95% CI: 90-99), and the OPA was 93% (95% CI: 89-96) ( Table 4 ). For the 383 patient samples in AURA2 that passed pathology review, the PPA (excluding invalid results) was 89% (95% CI: 85-93), the NPA was 98% (95% CI: 94-100), and the OPA was 92% (95% CI: 89-95) (see Table 4 ). Similarly, there was a high sensitivity and specificity when the cobas test results were compared with the NGS reference method for detection of the exon 19 deletion mutations and the L858R mutation (see Table 4 ).
Discussion
In screening for AURA extension and AURA2, the rate of T790M detection was similar, around 63%, and consistent with the data from Yu et al., 11 who also reported a 63% rate of T790M mutation detection in patients with NSCLC previously treated with gefitinib and erlotinib. 11 However, it must be acknowledged that despite instructions that patients should not be tested locally before central testing, prescreening of patients with the T790M mutation cannot be ruled out, and this could have elevated the rate of T790M detection.
The cobas tissue test was shown to be a sensitive and specific method for the detection of T790M mutations in FFPE tissue samples from patients who had progressed while undergoing at least one prior EGFR TKI regimen when compared with an NGS reference method. This is comparable to the sensitivity and specificity data for detection of EGFR exon 19 deletions and L858R mutation. A limitation of this study is that despite the high sensitivity of the cobas tissue test, there is a chance of a false-negative result. Tumor tissue analysis can be complemented by plasma circulating tumor DNA (ctDNA) analysis. In a separate study evaluating the clinical utility of the cobas EGFR Mutation Test v2 for the detection of T790M in plasma samples collected during screening for the AURA extension and AURA2 studies, a high sensitivity and specificity were observed when compared with NGS analysis of plasma ctDNA, and in a small number of cases, the T790M mutation was 
Total no. of patients with rare EGFR mutations detected 35 (5) G719X only detected in the plasma ctDNA but not in the tumor tissue sample. 23 The ethnic background of the patients (Asian versus non-Asian) did not appear to affect the rate of T790M detection across both the AURA extension and AURA2 studies. Similarly, the type of EGFR TKI received immediately before osimertinib did not appear to affect the rate of T790M detection. The rate of T790M detection after afatinib treatment was 69% across both studies, which is higher than reported in a recent study of T790M prevalence in patients with lung adenocarcinoma who acquired resistance to afatinib; 48% (20 of 42 according to postafatinib tissue samples). 14 Irrespective of ethnic background, T790M mutation appeared to occur in a higher proportion of tumors with exon 19 deletion mutations (pooled analysis, 73%) than in those with the L858R mutation (58%), suggesting an enrichment of the exon 19 deletion plus T790M mutation type in EGFR-mutant advanced NSCLC after treatment with an EGFR TKI. The patient population screened in AURA extension and AURA2 could have also received additional anticancer regimens. However, in a recent systematic review and meta-analysis of T790M mutations in patients with advanced NSCLC before initial treatment, the likelihood of T790M mutation coexisting with L858R was higher than that of coexisting with exon 19 deletions. 24 It is possible that patients harboring tumors with exon 19 deletions are under a greater selective pressure for resistance mechanisms against EGFR TKIs (i.e., T790M mutation) than those patients with L858R mutation. Although both mutation subtypes are linked to greater efficacy with first-line EGFR TKIs (gefitinib, erlotinib, or afatinib) than standard of care chemotherapy in EGFR mutation-positive advanced NSCLC, a trend toward improved clinical benefit has been observed in those patients harboring an exon 19 deletion versus L858R mutation. 3, 7, [25] [26] [27] [28] However, it may be that the higher proportion of cases of the exon 19 deletion plus T790M mutation subtype observed is being driven through intrinsic biological properties of tumors harboring exon 19 deletions, such as a higher probability of acquiring a second mutation in later-onset resistance (e.g., dimerization or conformational status after the exon 19 deletion may increase the probability of acquisition of T790M), or they may be more mutationally active than tumors with L858R mutations. Therefore, at the point of disease progression during treatment with an EGFR TKI, a higher rate of T790M detection might be predicted in those patients with exon 19 deletions versus L858R. It should be noted that in the total screened populations of both studies, a higher proportion of patients harbored an exon 19 deletion versus L858R mutation (approximately 2:1). Given the aforesaid observation, this may have influenced the T790M detection rates in these studies. The difference in exon 19 deletion versus L858R rates was most pronounced in the non-Asian populations, which is in line with patient characteristics reported in previous studies of EGFR TKIs in the first-line setting. 3, 26, 29 Rare EGFR mutations were detected in 5% of patients screened (and with a valid cobas test result): G719X (3%), S768I (1%), and exon 20 insertion (1%). The rates observed here for G719X and S768I are consistent with those observed in previous studies of EGFR mutations; the rate of exon 20 insertions appears lower than reported elsewhere. [30] [31] [32] In those patients without detectable common EGFR TKI sensitizing mutations (exon 19 deletion/L858R), rare EGFR mutations were detected in 3% of patients. However, the detection rate of rare EGFR mutations in the absence of exon 19 deletion and L858R should be interpreted with caution because of the inclusion criteria for AURA2 and AURA extension requiring confirmation of EGFR mutation known to be sensitive for EGFR TKIs, including G719X, exon 19 deletion, L858R, and L861Q. Partial responses to osimertinib were observed in most of the patients with tumors harboring rare EGFR mutations concomitantly detected with T790M. Among six patients who had T790M as their only detectable mutation, four had a partial response to osimertinib, which is consistent with the objective response rates observed in the overall osimertinib-treated populations in AURA extension and AURA2, 19, 20 although the number of patients is small and this result should not be overinterpreted.
In conclusion, this analysis demonstrates that the rate of T790M mutations detected in patients with advanced NSCLC and previous disease progression during treatment with an EGFR TKI is similar in the two registration studies conducted across different investigational sites, which is consistent with the rates reported in the literature and unaffected by immediately prior EGFR TKI or ethnicity.
